Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

234 results
Display

Influences of Patient Activation on Diabetes Self-Care Activities and Diabetes-Specific Distress

Choi S, Kim SH

PURPOSE: The purpose of the study was to evaluate the influence of patient activation on diabetes self-care activities and diabetes-specific distress among patients with type 2 diabetes mellitus. METHODS: This cross-sectional...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)

Chung YR, Ha KH, Lee K, Kim DJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)

Moon JS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome

Seo JB, Choi YK, Woo HI, Jung YA, Lee S, Lee S, Park M, Lee IK, Jung GS, Park KG

BACKGROUND: The hypoglycemic drugs dipeptidyl peptidase-4 (DPP-4) inhibitors have proven protective effects on diabetic kidney disease, including renal fibrosis. Although NOD-like receptor protein 3 (NLRP3) inflammasome activation is known to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study

Wang Z, Park H, Bae EJ

Dipeptidyl peptidase (DPP)-4 inhibitors, or gliptins, are a class of oral hypoglycemic drugs that have been widely used as a second-line treatment for type 2 diabetes. Gliptins, which were introduced...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-diabetic effects of blue honeyberry on high-fed-diet-induced type II diabetic mouse

Sharma A, Kim JW, Ku SK, Choi JS, Lee HJ

BACKGROUND/OBJECTIVE: The blue honeysuckle berry (Lonicera caerulea var. edulis L.) is a small deciduous shrub belonging to the Caprifoliaceae family that is native to Russia, China, Japan, and Korea. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Flaxseed Enriched Yogurt on the Glycemic Status and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus: Randomized, Open-labeled, Controlled Study

Hasaniani , Rahimlou M, Ramezani Ahmadi A, Mehdizadeh Khalifani A, Alizadeh M

Flaxseed is one of the rich sources of α-linolenic acid and lignan. Flaxseed and its components have antioxidant, hypolipidemic and hypoglycemic effects. The study aimed to investigate the effect of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study

Chung YR, Ha KH, Kim HC, Park SJ, Lee K, Kim DJ

BACKGROUND: To investigate the effects of dipeptidyl peptidase-4 inhibitor (DPP4i) as add-on medications to metformin on progression of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus, compared with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cancer Risk in Patients with Type 2 Diabetes on Antidiabetic Monotherapy: A Population Based Cohort Study Using National Insurance Health Service Database

Jung HY, Lee S

BACKGROUND: Diabetes is associated with cancer risk in the aging population. Observational studies have indicated the beneficial effects of metformin against breast cancer, making studies on the anticancer potential of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus

Ko SH

For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations

Lim S

Diabetes mellitus (DM) is linked to poor outcomes after cardiovascular events and renal complications. Recently, novel antidiabetic agents, such as dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-limb Roux-en-Y Reconstruction after Subtotal Gastrectomy to Treat Severe Diabetic Gastroparesis

Park JM, Kim JW, Chi KC

The role of surgical intervention in patients with diabetic gastroparesis is unclear. We report a case of a 37-year-old man with a history of recurrent episodes of vomiting and long-standing...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea

Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY

BACKGROUND: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacotherapy of Diabetes Focused on Stroke

Lyu YS, Kim JH, Kim SY

Cardiovascular disease, including stroke, is one of the major causes of death in diabetes. Numerous studies have long suggested reducing macrovascular complication such as ischemic vascular disease through intensive glycemic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic Effect of Quadruple Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus Who Have Insulin Limitations

Yoo WS, Kim DH, Kim HJ, Chung HK

BACKGROUND: Insulin therapy is the treatment of choice in type 2 diabetes mellitus (T2DM) patients who are not achieving glycemic goals despite triple oral hypoglycemic agent (OHA) combination therapy. However,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors

Hong JH

Management of hyperglycemia limits progression of microvascular complications in type 2 diabetes mellitus (T2DM). According to large-scale randomized control studies to demonstrate the cardiovascular safety of sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

Kim GS, Park JH, Won JC

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Influencing Glycemic Control among Type 2 Diabetes Mellitus Patients: The Sixth Korea National Health and Nutrition Examination Survey (2013~2015)

Gu MO

PURPOSE: This study was conducted to examine factors influencing glycemic control among type 2 Diabetes Mellitus (T2DM) patients using data from the sixth Korea National Health and Nutrition Examination Survey...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke

Ahn CH, Lim S

Patients with hyperglycemia are at a high risk of cardio- and cerebrovascular diseases. Diabetes patients also have poor outcomes after cerebrovascular disease development. Several classes of drugs are used for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Jung CH, Mok JO

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr